[Tactivin in combined treatment of patients with pulmonary tuberculosis associated with gastrointestinal diseases].
Tactivin was tried in combined therapy of 49 new-onset cases with destructive pulmonary tuberculosis and gastrointestinal lesions. 52 controls received antibacterial drugs alone. Tactivin increased T-lymphocyte count and improved their subpopulations proportion in a shorter period of time. Immunochemotherapy contributed to efficacy of the main and associated disease treatment. Healing of the destruction foci occurred in 87% versus 70% in controls, side effects of antibacterial drugs and exacerbations of gastrointestinal diseases arose 2-2.5 times less frequently.
Zhukova
E M
EM
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D002764:Cholecystitis / Q000150:complications; D003131:Combined Modality Therapy; D005756:Gastritis / Q000150:complications; D005767:Gastrointestinal Diseases / Q000150:complications*; D006801:Humans; D008875:Middle Aged; D010437:Peptic Ulcer / Q000150:complications; D010455:Peptides / Q000627:therapeutic use*; D012397:Rosette Formation; D013949:Thymus Extracts / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D000995:Antitubercular Agents; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin